arrow
Back
M

Miguel Martín

universidad complutense

107H-index
1.3KPaper Count
4.7WCitation Count
Published Papers 293
Publication Date
Age 35 in SOFT: Prognostic Boundary, Treatment-Effect Modifier, or Surrogate of Clinical Risk?
err2026-10-13
err0
PREAI
errR. Kumar; L. Costa; M.J.T.F.D. Vrancken-Peeters; M.E. Cazzaniga; J. Huober; A. Vaid; C. Garcia-Cantu; F.J. Esteva; M. Toi; M. Martin
errShare
errSave
Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups
err2026-09-30
err0
errOAAI
errJ. Cortes; S.R.D. Johnston; M. Martin; S.M. Tolaney; M.P. Goetz; H.S. Rugo; J. Sohn; O. Ozyilkan; M.H. Abreu; M. Zaiss; K.M. Vianna; H.M. Nielsen; A. Chan; H. Kalofonos; S. Morales; B.R. Grimes; S. Amdur; P. Neven
errShare
errSave
Trop-2 overexpression as a prognostic marker in early triple-negative breast cancer: results from the GEICAM_CIBOMA trial
err2026-08-28
err0
errOAAI
errFederico Rojo; Sara Lopez-Tarruella; Begoña Bermejo; Laura Torrecillas; Manuel Ruiz-Borrego; Jose Bines; Jose G. M. Segalla; Jose A. Garcia-Saenz; Roberto Torres; Juan de la Haba-Rodriguez; Elena Garcia-Martinez; Henry Gomez; Antonio Llombart-Cussac; Maria Rodriguez de la Borbolla; Laura Perez Michel; Margarita Amenedo; Isaura Fernandez; Alvaro Rodriguez-Lescure; Jesus Cardenas; Jeferson Vinholes; Eduardo Martinez de Dueñas; Vega Iranzo Gonzalez-Cruz; Miguel Angel Segui; Sandra Perez-Buira; Jesus Herranz; Raul Rincon; Rosalia Caballero; Carlos H. Barrios; Miguel Martin; Angel Guerrero-Zotano
errShare
errSave
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility
err2026-08-01
err0
PREAI
errTolaney, S. M.; Tung, N.; Wolff, A. C.; DeMichele, A.; Cejalvo, J. M.; Martinez-Saez, O.; Pascual, T.; Waks, A. G.; Nozawa, K.; Iwata, H.; Martin, M.; Ciruelos, E.; Harbeck, N.; Carey, L. A.; Cortes, J.; Llombart, A.; Sharma, P.; Curigliano, G.
errShare
errSave
Abemaciclib in HR+, HER2− Breast Cancer: A Narrative Review of the Clinical Evidence
err2026-06-15
err0
errOAAI
errMiguel Martin; Alexandru Rosca; Alexandra Searles Vitko; Monique Coersmeyer; Katheryn Moreira; Huiping Li; Erica L. Mayer
errShare
errSave
Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies
err2026-05-25
err0
errOAAI
errSonia Servitja; Eva Carrasco; Raquel Andrés; Álvaro Rodríguez-Lescure; Miguel Martín; Manuel Ruiz-Borrego; Ángel Guerrero; Begoña Bermejo; Antonio Antón; Montserrat Muñoz; Mireia Margeli; Isabel Álvarez; Luis Antonio Fernández; Jose Ponce; Josefina Cruz; Purificación Martínez; Sara López-Tarruella; Margarita Amenedo; Andrea Blasco; Óscar Polonio; Miguel Gil-Gil
errShare
errSave
Environmental Performance of Mature Precast Slabs in Permeable Pavements: Hydraulic Functionality and Pollutant Retention Under Real-Life Conditions
err2026-04-28
err0
errOAAI
errDarío Calzadilla-Cabrera; Eduardo García-Haba; Carmen Hernández-Crespo; Miguel Martín; Ignacio Andrés-Doménech
errShare
errSave
Breast cancer incidence and survival by subtype, stage at diagnosis and socioeconomic deprivation among young women in the Community of Madrid, Spain
err2025-12-05
err0
errOAAI
errCandela Pino-Rosón; Sonia Ávila-Arroyo; David Parra-Blázquez; María J. Soto Zabalgogeazcoa; Daniel Moñino; Raquel López-González; Clotilde Sevilla-Hernández; Cristina González-Blázquez; Miguel Martín; Nuria Aragonés
errShare
errSave
Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges
err2025-11-06
err0
errOAAI
errMark Verrill; Michael Patrick Lux; Joseph Gligorov; Jürgen Geisler; Renata Duchnowska; Beatrix Elsberger; Miguel Martin
errShare
errSave
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆
err2025-10-17
err0
errOAAI
errJ. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
errShare
errSave
Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
err2025-04-01
err0
PREAI
errHarbeck, N.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Martin, M.; Neven, P.; Kim, S.; Ma, J.; Gauthier, E.; Broughton, E.; Doan, J.; Rugo, H. S.
errShare
errSave
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy☆
err2025-03-24
err0
PREAI
errS. Loibl; M. Martin; H. Bonnefoi; M. Untch; S.-B. Kim; H.D. Bear; J.A. García-Sáenz; M. Melé Olivé; N. Mc Carthy; K. Gelmon; C.M. Kelly; S.-A. Im; T. Reimer; M. Martinez-Janez; Z. Zhang; M. Toi; L. Provencher; H.S. Rugo; M. Gnant; A. Makris; F. Marmé
errShare
errSave
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
err2025-02-13
err0
errOAAI
errMukhtar, Rita A.; Gottipati, Soumya; Yau, Christina; Lopez-Tarruella, Sara; Earl, Helena; Hayward, Larry; Hiller, Louise; Osdoit, Marie; van der Noordaa, Marieke; de Croze, Diane; Hamy, Anne-Sophie; Lae, Marick; Reyal, Fabien; Sonke, Gabe S.; Steenbruggen, Tessa G.; van Seijen, Maartje; Wesseling, Jelle; Martin, Miguel; del Monte-Millan, Maria; Boughey, Judy C.; Goetz, Matthew P.; Hoskin, Tanya; Valero, Vicente; Edge, Stephen B.; Abraham, Jean E.; Bartlett, John M. S.; Caldas, Carlos; Dunn, Janet; Provenzano, Elena; Sammut, Stephen-John; Thomas, Jeremy S.; Graham, Ashley; Hall, Peter; Mackintosh, Lorna; Fan, Fang; Godwin, Andrew K.; Schwensen, Kelsey; Sharma, Priyanka; Demichele, Angela M.; Cole, Kimberly; Pusztai, Lajos; Kim, Mi-Ok; van 't Veer, Laura; Cameron, David; Esserman, Laura J.; Fraser Symmans, W.
errShare
errSave
HER2DX genomic test in early-stage HER2-positive breast cancer
err2024-12-01
err0
PREAI
errTolaney, S. M.; Tung, N.; Wolff, A. C.; DeMichele, A.; Cejalvo, J. M.; Martinez-Saez, O.; Pascual, T.; Waks, A. G.; Martin, M.; Ciruelos, E.; Harbeck, N.; Carey, L. A.; Cortes, J.; Curigliano, G.; Prat, A.
errShare
errSave
Gestational breast cancer: distinctive molecular and clinico-epidemiological features
err2024-11-08
err1
errOAAI
errde la Haba-Rodriguez, J. R.; Minguez, P.; Rojo, F.; Martin, M.; Alba, E.; Servitja, S.; Prat, A.; Perez-Fidalgo, J. A.; Gavila, J.; Morales, C.; Rodriguez-Lescure, A.; Herrero, C.; Pena-Enriquez, R.; Herranz, J.; Hernando, C.; Hernandez-Blanquisett, A.; Guil-Luna, S.; Martinez, M. T.; Blanch, S.; Caballero, R.; Martin, N.; Pollan, M.; Guerrero-Zotano, A.; Bermejo, B.
errShare
errSave
Laser transfer for circulating tumor cell isolation in liquid biopsy
err2024-08-01
err1
errOAAI
errMolpeceres, Carlos; Ramos-Medina, Rocio; Marquez, Andres; Romero, Paula; Gomez-Fontela, Miguel; Candorcio-Simon, Rocio; Munoz, Andres; Lauzurica, Sara; del Monte-Millan, Maria; Morales, Miguel; Munoz-Martin, David; Lopez-Tarruella, Sara; Massarrah, Tatiana; Martin, Miguel
errShare
errSave
Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
err2024-07-18
err0
errOAAI
errD. Johnston, Stephen R.; Rugo, Hope S.; Tolaney, Sara M.; Fernandez, Maria Munoz; Wei, Ran; Martin, Miguel
errShare
errSave
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
err2024-07-01
err4
errOAAI
errDent, R.; Andre, F.; Goncalves, A.; Martin, M.; Schmid, P.; Schuetz, F.; Kuemmel, S.; Swain, S. M.; Bilici, A.; Loirat, D.; Valencia, R. Villalobos; Im, S. -A; Park, Y. H.; De Laurentis, M.; Colleoni, M.; Guarneri, V.; Bianchini, G.; Li, H.; Machackova, Z. Kirchmayer; Mouta, J.; Deurloo, R.; Gan, X.; Fan, M.; Mani, A.; Swat, A.; Cortes, J.
errShare
errSave
Trastuzumab deruxtecan in breast cancer
err2024-06-01
err8
errOAAI
errMartin, Miguel; Pandiella, Atanasio; Vargas-Castrillon, Emilio; Diaz-Rodriguez, Elena; Iglesias-Hernangomez, Teresa; Cano, Concha Martinez; Fernandez-Cuesta, Ines; Winkow, Elena; Perello, Maria Francesca
errShare
errSave
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2-advanced breast cancer: a real-world evidence cohort
err2024-05-04
err8
PREAI
errSanchez-Bayona, Rodrigo; de Sa, Alfonso Lopez; Gilarranz, Yolanda Jerez; de Torre, Ana Sanchez; Alva, Manuel; Echavarria, Isabel; Moreno, Fernando; Tolosa, Pablo; Lopez, Blanca Herrero; de Luna, Alicia; Lema, Laura; Casado, Salvador Gamez; Madariaga, Ainhoa; Lopez-Tarruella, Sara; Manso, Luis; Bueno-Muino, Coralia; Garcia-Saenz, Jose A.; Ciruelos, Eva; Martin, Miguel
errShare
errSave